Key Takeaways
- Sharp revenue drop, margin squeezed: Revenue fell 22% YoY as deficient monsoons hit domestic herbicide application and export demand softened; EBITDA margin compressed to 14.4% from 18.2% in Q2 FY26.
- Export order book offers near-term floor: Export orders received for Q3 and Q4, a mix of technicals and bulk formulations, provide support to the outlook and should help recover the H1 export shortfall.
- Registration engine is unlocking fresh geographies: UK technical equivalence and Argentina product registration were secured this quarter, opening Argentina where the company had zero prior business.
- Hamirpur subsidiary is live but being replanned: Two blocks were capitalized in September, yet the full product portfolio is being revisited because geopolitics has shifted raw-material availability and demand patterns.
- What to watch next quarter: Whether the Q3 export orders convert into the promised H2 catch-up, how quickly Argentina and UK registrations commercialize, and what the Hamirpur portfolio reset actually changes.
Revenue: The H1 Miss and the H2 Bet
- Monsoon broke the domestic story: Deficient and erratic rainfall across key paddy-growing states (Maharashtra, Andhra Pradesh, Karnataka, Telangana, Punjab, Haryana) reduced herbicide application, directly cutting domestic offtake.
- Exports weakened materially: H1 FY27 export revenue was ₹177 crores, down from ₹229 crores in H1 FY26, driven by softer overseas herbicide demand and geopolitical uncertainty.
- Formulation share rose even after adjusting for bulk: Formulation sales jumped from ₹72 crores to ₹111 crores QoQ; the increase holds after stripping out incremental bulk formulation exports, indicating a genuine mix shift Y-o-Y.
- Gross margin held at 50%: Product mix helped defend gross margin, which was better YoY despite the top-line pressure, though after adjusting for incremental job work charges it would be lower by 3%.
- Inventory overhang from deferred orders: Export orders expected in Q2 slipped into Q3, and a rice herbicide saw lower Q1 sales, leaving inventory elevated; management expects normalization by Q4, supported by good Q3 inquiries for that rice herbicide.
- The H2 bet is catch-up, not growth: Management aims to at least match last year's full-year revenue, implying H2 must be similar to or slightly better than H2 FY26 to compensate for the H1 shortfall; export orders already in hand are the basis for that confidence.
D.K. Jain: "Sir, whatever we are lagging in half year, at least we want to cover this up in the coming 6 months."
Margins: Compressed but Defended
- EBITDA margin fell 380 bps YoY: Q2 margin dropped to 14.4% from 18.2%, and the H1 margin fell from 18.6% to 14.9%, driven by higher employee expenses and lower forex income.
- Job-work charges doubled: Other expenses rose YoY partly because job work charges increased to ~₹12 crores from ~₹6 crores, as the company shifted from buying an intermediate directly to getting raw material converted through job work.
- Management is confident of holding the current margin: The stated view is that the Q2 EBITDA margin level is maintainable, though no expansion commitment was made.
D.K. Jain: "We are quite confident that we should be able to maintain the EBITDA margin what we have achieved in this quarter."
Registration-Led Market Access
- UK technical equivalence approved: One insecticide product received technical equivalence in the United Kingdom; existing customers have taken a letter of access, and business is expected in coming months.
- Argentina registration secured: One herbicide product was registered, and a distribution agreement has been finalized; this is a fresh market with no prior business, and the company anticipates ₹20–25 crores in the first year from this single molecule, with a second molecule registration already underway.
- Europe equivalence already converting: Orders have started coming from Europe for formulated product sold to formulators there, building on the prior EU approval.
- Pipeline is deepening: Four more products have been applied for registry equivalents in Europe, four more are in data generation, and a total stream of roughly eight products will be applied across Australia, Europe, Brazil, and Canada, widening the addressable geography and customer base.
- No timeline for UK and Argentina commercialization: Management did not specify when revenue from these newly approved products will begin, only that business is expected in coming months.
Hamirpur Subsidiary: Live but Under Review
- Plant is operational and capitalized: Two blocks became operational and were capitalized in September (~₹65 crores), with central infrastructure including roads, boilers, and chillers already in place.
- Product portfolio is being reset: Management is revisiting the complete product portfolio planned for the subsidiary because geopolitical conditions have made some raw materials difficult to source, prices have fluctuated sharply, and demand patterns are shifting.
- Flexibility is the hedge: The plant is multipurpose by design, so switching from one product to another requires only minor modifications; the company is selecting from its already-approved product basket rather than developing entirely new molecules, and can revert to earlier products if demand returns.
- Revenue expectations are modest for now: The subsidiary is expected to generate ₹40–50 crores of turnover in H2 FY27, with a target of at least ₹80 crores of additional revenue next year on an incremental capex of ~₹40 crores (asset turn of 2).
- Two more blocks planned: Two additional blocks are expected to become operational "most probably next year," with all 10 blocks coming online gradually.
D.K. Jain: "Because of the geopolitical situation, some of the raw materials availability has become difficult. Some prices have fluctuated a lot and the demand pattern is also changing. So considering all these aspects, we are revisiting the complete portfolio what we have planned, especially for our subsidiary."
Backward Integration: The Quiet Margin Story
- Pretilachlor intermediate indigenized: The major intermediate for the herbicide Pretilachlor is now being produced in-house using internally developed R&D technology, and imports of this intermediate have "more or less totally stopped."
- Two more molecules backward-integrated: Intermediate production facilities have been developed for two additional molecules, extending the integration playbook beyond Pretilachlor.
- More to come: The company is continuing to develop backward-integrated intermediate production for other technicals, a structural lever for margin defense that sits independent of the demand cycle.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Full-year revenue | At least match FY26 revenue (₹295 cr in Q2 FY26; full-year figure not restated) | FY27 |
| H2 revenue | Similar to or slightly better than H2 FY26 to partially compensate for H1 shortfall | H2 FY27 |
| EBITDA margin | Maintain Q2 FY27 level (14.4%) | Ongoing |
| Subsidiary turnover | ₹40–50 crores | H2 FY27 |
| Subsidiary next-year revenue | At least ₹80 crores additional revenue on ~₹40 crores incremental capex | FY28 |
| Argentina first-year revenue | ₹20–25 crores from the single registered molecule | First year (undated start) |
| Inventory normalization | Normalize by Q4 FY27, supported by good Q3 inquiries for rice herbicide | Q4 FY27 |
| Hamirpur block expansion | Two more blocks operational | "Most probably next year" |
| Capex (IPL standalone) | ₹40–45 crores | FY27 |
| Capex (subsidiary) | ₹80–90 crores; second phase being revisited, funded as need arises | FY27 |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Revenue | ₹231 cr, -22% YoY from ₹295 cr in Q2 FY26 |
| EBITDA | ₹33 cr, margin of 14.4% vs ₹54 cr and 18.2% in Q2 FY26 |
| Profit after tax | ₹18 cr, margin of 8% vs ₹32 cr in Q2 FY26 |
| Revenue from technicals and API | ₹115 cr |
| Formulation revenue | ₹111 cr, up from ₹72 cr in Q1 FY27, one of the highest in several quarters |
| H1 FY27 revenue | ₹487 cr, -15.9% YoY from ₹579 cr in H1 FY26 |
| H1 FY27 EBITDA | ₹73 cr, margin of 14.9% vs ₹108 cr and 18.6% in H1 FY26 |
| H1 FY27 PAT | ₹41 cr, margin of 8.5% vs ₹67 cr and PAT margin of 8.5% in H1 FY26 |
| H1 FY27 export revenue | ₹177 cr vs ₹229 cr in H1 FY26 |
| H1 FY27 operating cash flow | ₹48 cr |
| Net cash (consolidated) | ₹36 cr as on 30 Sep 2026, up from ₹29 cr as at March end |
| Gross margin | ~50%, better YoY; adjusted for incremental job work charges would be lower by 3 ppt but still higher YoY due to product mix |
| Job work charges | ~₹12 cr vs ~₹6 cr in Q2 FY26, included in other expenses |
| Export orders on hand | ~₹100 cr from Europe and Australia, partially executed, partly to be executed in coming months |
| Backward integration | ~75% of products backward integrated |
| Raw material sourcing | >65% from India, ~20% from China, remainder from other countries |
| Installed capacity (technicals) | 28,300 MT across Dewa Road and Sandila; Hamirpur permitted capacity 30,000 MT |
| Installed capacity (formulations) | 10,200 MT across Dewa Road and Sandila; Hamirpur permitted capacity 6,000 MT |
| Hamirpur blocks operational | 2 of 10 blocks operational, 2 additional blocks expected operational early next year |
| Subsidiary capitalization | ~₹65 cr in September 2026, expected H2 FY27 turnover of ₹40–50 cr from subsidiary |
| Capex guidance (standalone) | ₹40–45 cr, on track |
| Capex guidance (subsidiary) | ₹80–90 cr, second phase being revisited, short of earlier ₹120–130 cr guidance |
| Argentina new market anticipation | ₹20–25 cr first-year business from a single molecule |
| Sales network | 18 states, 24 depots, 6 zonal offices, ~405 sales personnel |
| R&D | 2 DSIR-recognized centers, 25 scientists |